Curium, a world leader in nuclear medicine, announced today that it has expanded its existing partnership with Institute of ...
Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer. PYLCLARI® (INN: Piflufolastat (1 ...
PARIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with ...
Ciril Faia, Chief Executive Officer, Curium Pharma Europe ... a contract manufacturing organization in the field of nuclear medicine. It underscores the trust placed in our teams and the quality ...
PARIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop ...
Curium, a world leader in nuclear medicine, announced that Pylclari is now available for patients with prostate cancer in Estonia, Finland, Latvia, and Sweden. Pylclari (INN: Piflufolastat (18F) also ...
A nuclear medicine company has signed a new letting deal at Lakeside North Harbour in Portsmouth.
For context, curium isotopes are not only radiotoxic ... Learning more about them may benefit fields ranging from cancer medicine to nuclear energy to the synthesis of new elements.